Impact Of Dose Modifications On Ocular Adverse Events In Phase 3 Mirasol Trial Of Mirvetuximab Soravtansine-Gynx Vs Investigator’S Choice Chemotherapy In Recurrent, Folate Receptor Alpha -Positive, Platinum-Resistant Ovarian Cancer